Because cancer is prone to recurrence, the clinical cure rate of cancer, clinically, is generally referred to the 5-year survival rate. The 5-year survival rate of triple-negative breast cancer is closely related to the stage of breast cancer. The 5-year survival rate of early-stage triple-negative breast cancer is about 77%, and the 5-year survival rate of late-stage triple-negative breast cancer is about 14%. Triple negative breast cancer refers to breast cancer that is negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. This type of breast cancer accounts for about 15-20% of all breast cancer patients. Triple negative breast cancer lacks effective therapeutic targets and is insensitive to common endocrine therapy and targeted therapy. The current treatment for triple negative breast cancer is limited, and the main treatment methods are surgery and chemotherapy, and the treatment drugs are mainly two-drug combination regimens containing platinum drugs. Chemotherapeutic drugs can prolong the survival of patients with advanced triple negative breast cancer to some extent, but the effect is limited and the quality of life of patients will be affected by high intensity chemotherapy, so this type of breast cancer has a poor prognosis and is prone to recurrence and metastasis in the early stage, which is expected to be targeted after precise staging to improve the 5-year survival rate.